
Eikon Therapeutics reports promising Phase 2 NSCLC and Phase 1/2 solid tumor trial data at ASCO 2026
Eikon Therapeutics presented updated clinical data at the 2026 ASCO meeting showing encouraging results for its EIK1001 drug in first-line treatment of stage 4 non-small cell lung cancer (NSCLC), with a 63.1% response rate and good tolerability. The ...


